Skip to main content
Medical information Clinical review pending

Cytogenetics

FISH MYCN Amplification Test

The FISH MYCN Amplification Test detects MYCN gene amplifications, often linked to aggressive cancers like neuroblastoma, helping guide treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue.
Results
Results are typically available within 4 working days after sample receipt. Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the tissue block is properly labeled and accompanied by a completed Chromosome & FISH analysis Requisition Form (Form 17).
Test priceKSh 24,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FISH MYCN Amplification Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis or monitoring of neuroblastoma.
  • ✓Assessment of cancer aggressiveness.
  • ✓Guiding treatment decisions in specific cancers.
  • ✓Patients with suspected MYCN amplification.
  • ✓Prognostic evaluation in certain tumor types.
02

In plain language

What this test helps you understand

This test helps identify MYCN gene amplification in tumor tissue, which is a significant prognostic factor in certain cancers, particularly neuroblastoma. It aids oncologists in assessing disease risk and guiding treatment decisions.
The FISH MYCN Amplification Test is a specialized diagnostic procedure used to identify MYCN gene amplifications. These genetic changes are frequently associated with aggressive forms of cancer, particularly neuroblastoma. This test utilizes Fluorescence In Situ Hybridization (FISH) technology to examine tumor tissue samples for the presence of these amplifications.

This test specifically measures the number of copies of the MYCN gene within cancer cells. An increased number of copies (amplification) can indicate a higher risk of disease progression and may influence treatment strategies.

Patients diagnosed with neuroblastoma or other cancers where MYCN amplification is a known factor should discuss this test with their oncologist. It provides crucial information for understanding the potential aggressiveness of the cancer and tailoring treatment plans accordingly.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the tissue block is properly labeled and accompanied by a completed Chromosome & FISH analysis Requisition Form (Form 17).
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue.
MethodologyFluorescence In Situ Hybridization (FISH).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
The test requires adequate tumor tissue in the sample. Results are specific to the tissue provided and may not reflect the entire tumor or potential metastatic sites. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

MYCN amplification means there are extra copies of the MYCN gene in cancer cells. This can be associated with more aggressive cancer behavior.
Identifying MYCN amplification helps doctors understand the potential risk associated with a cancer and choose the most appropriate treatment plan.
A formalin-fixed paraffin-embedded (FFPE) tissue block containing tumor cells is required for this test.
Results are typically available within 4 working days after the laboratory receives the sample. Confirm with the laboratory before booking.
A positive result indicates that MYCN gene amplification was detected in the sample. Your doctor will discuss the implications of this finding with you.
You can book the test by contacting us at +254711564616 or visiting one of our laboratory branches. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp